In the course of our chemical studies on marine-derived tetrahydroisoquinoline alkaloids ( Fig. 1) , 1) we recently succeeded in preparing the ABC ring model compound of renieramycin G (1g) through the stereoselective Pictet-Spengler-type cyclization of N-methyl-3-arylmethylpiperazine-2,5-dione with ethyl diethoxyacetate.
In the course of our chemical studies on marine-derived tetrahydroisoquinoline alkaloids ( Fig. 1) , 1) we recently succeeded in preparing the ABC ring model compound of renieramycin G (1g) through the stereoselective Pictet-Spengler-type cyclization of N-methyl-3-arylmethylpiperazine-2,5-dione with ethyl diethoxyacetate.
2) Encouraged by the results of model studies, we report here a nine-step synthesis of the pentacyclic framework for the total synthesis of cribrostatin 4 (2) along with renieramycin I (1i).
A mixture of 3-arylidene-6-arylmethylpiperazinedione 3 3) and 3 eq of triethylamine (TEA) was treated with trimethylsilyl chloride (TMSCl, 3 eq) in dichloroethane at 25°C for 1 h to afford the O-trimethylsilyllactim intermediate. This intermediate was treated with ethyl diethoxyacetate (1.5 eq) in the presence of trimethylsilyl trifluoromethanesulfonate (TMSOTf) at 25°C for 19 h, and then refluxed for 1 h to give 4 in 72% yield as a single isomer (Chart 1). The stereochemistry of 4 was undetermined at this stage, but 1 H-NMR measurement showed a C-1 4) proton signal at d 6.60. Then, we studied the chemoselective reduction of the ester carbonyl of 4 to the hydroxymethyl group at C1 position. Encouraged by the results of our model studies, 2) we applied the three-step transformation of 4 to corresponding alcohol 5 (1, hydrolysis; 2, mixed anhydride preparation; 3, NaBH 4 reduction), but the overall yield was 53%. For the reduction step, we found it best to establish a direct method for the construction of a 1-hydroxymethyl derivative from 3. Cyclization of 3 with 2,2-diethoxyethyl benzoate 5) using the above two steps afforded 5 in 83% overall yield. X-ray crystallographic analysis of 5 proved that the stereochemistry was trans between C1 and C3 protons (Fig. 2) . This stereoselective cyclization would proceed from the less hindered a-face to the (E)-iminium isomer.
The next stage of our investigation involved the establishment of a method to construct the cis stereochemistry between C3 and C13. Catalytic reduction of the double bond of 5 in the presence of 10% Pd/C gave 6a in 93% yield along with corresponding trans diastereomer 6b in 3% yield. The cis stereochemical assignment of 6a is based on 1 H-NMR spectral evidence. The d value of b-axial proton at C4 position of 6a (d 1.94) indicates that this proton is positioned in the deshielding zone of the aromatic ring of the side chain at C13 position, and differs from the d values of d 2.87 and d 2.92 appearing in the 1 H-NMR spectra of 5 and 6b, respectively. Thus, the hydrogenation of 5 has obviously occurred stereoselectively from the a-face to generate cis isomer 6a. The bulky substituents at C1 would exert enough steric influence on the course of the reduction (Chart 2). The catalytic reduction of 12, which was obtained from 5 by hydrolysis in 96% yield, gave cis isomer 13a (d 1.88 at 4-Hb; 54%) and trans isomer 13b (d 2.73 at 4-Hb; 28%). On the contrast, the catalytic reduction of 14, which was prepared from 12 by silylation in 80% yield, afforded mainly trans isomer 15b (d 2.71 at 4-Hb) in 33% yield along with cis isomer 15a (d 1.94 at 4-Hb; 15%). The structures of these products (6a, 13a, 15a) were confirmed by direct comparison chemically transformed compounds. 6, 7) Finally, we studied the construction of the D ring to generate the pentacyclic framework of renieramycins. The piperazine ring of 6a was activated by the introduction of a 2-propyloxycarbonyl group to give imide 7 in 82% yield. The chemoselective reduction of 7 with lithium tri-tert-butoxyaluminum hydride in tetrahydrofuran (THF) afforded a diastereomeric mixture of aminals, which was converted into a cyclized product by exposure to formic acid at 60°C for 14 h. Surprisingly, it was unexpected dehydrogenated compound 8 (80%). The mechanistic pathway for this transformation is unclear at this stage, but it can be presumed that after the dehydration of the aminals (i) to generate an iminium ion species (ii), rapid isomerization followed by a spontaneous oxidation of iii and cyclization sequence afforded 8 (Chart 3). 8, 9) The deprotection of 8 with trifluoroacetic acid (TFA) and H 2 SO 4 at 25°C for 10 h gave secondary amine 9 (96%), the stereochemical structure of which was confirmed by X-ray crystallographic analysis (Fig. 3) . Reductive methylation of 9 with formaldehyde and formic acid at 70°C for 1 h afforded compound 10 (97%). Hydrolysis of 10 with 1 M LiOH/H 2 O in THF and MeOH at 25°C for 2 h gave alcohol 11 in quantitative yield.
In summary, we have succeeded in the nine-step transformation of pentacyclic compound 11 from readily available 3 in high yield. To date, a number of elegant total syntheses of renieramycins A (1a), 10) G (1g), [11] [12] [13] [14] and cribrostatin 4 (2) [15] [16] [17] have been reported and almost all of them include the construction of the bicyclic AB ring system with a cis relationship at C1 and C3 positions, followed by condensation of the E ring part and elaboration of the central bridged CD ring. Our strategy for the total synthesis of 2 along with renieramycin I (1i) might be prepare 1-epi-pentacycles, but, undesired stereochemistry might be inverted to natural one at C-1 position on the basis of our previous synthetic studies on saframycin antibiotics. 18, 19) Our route might be provided both natural and unnatural derivatives as part of a broad study of this family of biologically active compounds. Efforts to investigate the isomerization at C1 position of 11 and its application to the total synthesis of cribrostatin 4 along with its derivatives are under way. 3) (50.0 mg, 0.1 mmol) in ClCH 2 CH 2 Cl (1 ml) and TEA (41.8 ml, 0.3 mmol), and the stirring was continued at 25°C for 1 h. A solution of ethyl diethoxyacetate (26.7 ml, 0.15 mmol) in ClCH 2 CH 2 Cl (1 ml) followed by TMSOTf (108.6 ml, 0.6 mmol) was added dropwise respectively over 5 min, and the reaction mixture was stirred at 25°C for 19 h. After TLC monitoring revealed that all of starting material 3 had been consumed, the reaction mixture was refluxed for 1 h. Then, the reaction mixture was diluted with water (10 ml), made alkaline with saturated NaHCO 3 solution, and extracted with CHCl 3 (20 mlϫ3 ). The combined extracts were washed with brine (20 ml), dried, and concentrated in vacuo. The residue was subjected to column chromatography with ethyl acetate-hexane (1 : 3) to give 4 (42.0 mg, 72%) as a yellow amorphous powder. Three-Step Preparation of 5 from 4: Lithium hydroxide monohydrate (6.9 mg, 0.164 mmol) was added to a stirred solution of 4 (40.0 mg, 0.068 mmol) in THF (0.46 ml) and MeOH (0.14 ml), and the resulting solution was stirred at 25°C for 48 h. The reaction mixture was poured into water (20 ml), acidified with 1 N HCl, and extracted with chloroform (20 mlϫ3). The combined extracts were washed with brine (20 ml), dried, and concentrated in vacuo to give a carboxylic acid (39.4 mg), which was used in the next step without further purification. Ethyl chloroformate (0.008 ml, 0.082 mmol) was added to a stirred solution of the above residue and TEA (0.011 ml, 0.079 mmol) in THF (1.2 ml) at 25°C. The reaction mixture was stirred at ϩ5°C for 4 h, and then at 25°C for 13 h. After filtration of the mixture with THF (3 ml), a suspension of sodium borohydride (3.1 mg, 0.082 mmol) in water (0.04 ml) was added to the combined filtrate at 0°C and stirring was continued for 5 h at the same temperature. The reaction mixture was poured into saturated aqueous NH 4 Cl solution (30 ml) and extracted with chloroform (30 mlϫ3). The combined extracts were washed with brine (30 ml), dried, and concentrated in vacuo to give a residue (39.2 mg). The residue was subjected to column chromatography with ethyl acetate-hexane (1 : 2) to give 5 (19.7 mg, 53%) as a pale yellow solid.
Direct Transformation of 5 from 3: TMSCl (0.38 ml, 3.0 mmol) was added to a stirred solution of 3 (500.0 mg, 1.0 mmol) in dichloroethane (10 ml) and TEA (0.42 ml, 3.0 mmol), and the stirring was continued at 25°C for 1 h. A solution of 2,2-diethoxyethyl benzoate 5) (327.0 mg, 1.5 mmol) in ClCH 2 CH 2 Cl (10 ml) followed by TMSOTf (0.11 ml, 6.0 mmol) was added dropwise respectively over 5 min, and the reaction mixture was stirred at 25°C for 19 h. The reaction mixture was diluted with water (50 ml), made alkaline with saturated NaHCO 3 solution, and extracted with CHCl 3 (200 mlϫ3). The combined extracts were washed with brine (200 ml), dried, and concentrated in vacuo. The residue was subjected to column chromatography with ethyl acetate-hexane (1 : 4-1 : 3) to give 5 (533.0 mg, 83%) as a colorless solid, the recrystallization of which from ethyl acetate-hexane gave 5 as colorless prisms, mp Hydrogenation of Compound 5 A solution of 5 (1.29g, 2 mmol) in MeOH (50.0 ml) was hydrogenated over 10% Pd/C (640 mg) at 25°C for 40 h. The catalyst was removed by filtration and washed with MeOH. The combined filtrates were concentrated in vacuo to give a solid, the recrystallization of which from CHCl 3 -hexane gave 6a (1.20 g, 93%) as colorless prisms. After the mother liquor was concentrated, the resulting residue was purified by silica gel chromatography with from hexane-ethyl acetateϭ1 : 1.5 to ethyl acetate-MeOHϭ10 : 1 to give 6b (39.0 mg, 3%) as a colorless amorphous powder.
(3S*,6S*,11aS*)-9-Methyl-3-(3-methyl-2,4,5-trimethoxybenzyl)-6-phenylcarbonyloxymethyl-2,3,11,11a-tetrahydro-7,8,10-trimethoxy-6H-pyrazino [1,2-b] 
Hydrogenation of Compound 12
The same procedure as described above but using 12 (40 mg, 0.077 mmol) and 10% Pd/C (25.0 mg) in MeOH (1 ml) at 25°C for 5.5 h gave 13a (22.8 mg, 54.0%) and 13b (11.7 mg, 28.0%).
(3S*,6S*,11aS*)-6-Hydroxymethyl-9-methyl-3-(3-methyl-2,4,5-trimethoxybenzyl)-2,3,11,11a-tetrahydro-7,8,10-trimethoxy-6H-pyrazino [ Hydrogenation of Compound 14 The same procedure as described above but using 14 (19.5 mg, 0.025 mmol) and 10% Pd/C (8.1 mg) in MeOH (1 ml) at 2 MPa for 5.5 h gave 15a (2.9 mg, 15.0%) and 15b (6.4 mg, 33.0%).
(3S*,6S*,11aS*)-6-tert-Butyldiphenylsilyloxymethyl-9-methyl-3- (3-methyl-2,4,5-trimethoxybenzyl)-2,3,11,11a-tetrahydro-7 2,3,11,11a-tetrahydro-7,8,10-trimethoxy-6H-pyrazino[1,2-b]isoquinoline-1,4-dione (12) An aqueous 0.1 M solution of lithium hydroxide monohydrate (11.6 ml, 1.16 mmol) was added to a solution of 6b (600 mg, 0.93 mmol) in THF (35 ml) and MeOH (12 ml), and the reaction mixture was stirred at 25°C for 7 h. The reaction mixture was diluted with water (200 ml) and extracted with CHCl 3 (200 mlϫ3). The combined extracts were washed with brine (200 ml), dried, and concentrated in vacuo and the residue was purified by silica gel chromatography with MeOH-CHCl 3 (1 : 100) to give 12 (383.8 mg, 96%) as a colorless amorphous powder. 1 7 mg, 0.036 mol) , N,N-dimethylaminopyridine (DMAP) (6.6 mg, 0.055 mol), and imidazole (18.6 mg, 0.27 mmol) in dry THF (1.0 ml) at 25°C, and the reaction mixture was heated under reflux for 3 h. After cooling, the reaction mixture was poured into water (20 ml) and extracted with ethyl acetate (20 mlϫ3 ). The combined extracts were washed with brine (20 ml), dried, and concentrated in vacuo to give a residue (60.2 mg). Chromatography on a silica gel column with hexane-ethyl acetate (4 : 1-3 : 1) gave 14 (22.7 Conversion of 13a into 6a Benzoyl chloride (4.0 mg, 0.028 mmol) was added to a stirred solution of 13a (15.0 mg, 0.023 mmol) with TEA (0.004 ml, 0.028 mmol) and DMAP (0.7 mg, 0.0055 mmol) in dichloromethane (1.0 ml) at 25°C, and this mixture was stirred at the same temperature for 1.5 h. The reaction mixture was concentrated in vacuo and chromatography on a silica gel column with hexane-ethyl acetate (3 : 1) afforded 6a (16.3 mg, 91%) as colorless prisms, whose spectral data were in complete agreement with those of the authentic sample described above.
Conversion of 13a into 15a The same procedure as described above (from 5 to 14) but using 13a (20.0 mg, 36.8 mmol) gave TBDPS derivative (28.3 mg, 99%) as a pale yellow oil, whose spectral data were in complete agreement with those of minor product 15a.
(3S*,6S*,11aS*)-2-Isopropyloxycarbonyl-6-phenylcarbonyloxymethyl-9-methyl-3- (3-methyl-2,4,5-trimethoxybenzyl)-2,3,11,11a-tetrahydro-7,8,10-trimethoxy-6H-pyrazino[1,2-b]soquinoline-1,4-dione (7) A solution of 6a (500 mg, 0.772 mmol), TEA (0.21 ml, 1.54 mmol), and DMAP (188.0 mg, 1.54 mmol) in dichloromethane (15 ml) was cooled with icewater and isopropyl chloroformate (ClCO 2 Pr i , 0.425 ml, 3.09 mmol) was added dropwise over 10 min. After stirring at 25°C for 8 h, the reaction mixture was diluted with CH 2 Cl 2 (200 ml) and washed with 1 N HCl (50 mlϫ2). The combined extracts were washed with water (100 ml), dried, and concentrated in vacuo. The residue was purified by silica gel chromatography with hexane-ethyl acetate (1 : 4) to afford 7 (462.0 mg, 82%) as a colorless amorphous powder. 1 .313 mmol) in dry THF (9 ml) was cooled with ice-water and lithium tri-tert-butoxyaluminohydride (319.0 mg, 1.25 mmol) was added over 10 min. After continued stirring at 0°C for 2.5 h, Na 2 SO 4 was added and the reaction mixture was quenched with water (5 ml). The reaction mixture was filtered through Celite pad and the filtrate was concentrated in vacuo to give a residue that was used in the next step without further purification. A solution of the above residue in formic acid (5 ml) was stirred at 60°C for 14 h. After the reaction mixture was concentrated in vacuo, the residue was dissolved with CHCl 3 (80 ml) and 5% aqueous NaHCO 3 solution (80 ml). The phases were allowed to separate and the aqueous phase was extracted with CHCl 3 (80 mlϫ3). The combined extracts were washed with brine (80 ml), dried, and concentrated in vacuo to give a residue, the purification of which by silica gel column chromatography with ethyl acetate to ethyl acetate-MeOH (20 : 1) gave 8 (179.0 mg, 80%) as a pale yellow amorphous powder.
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